Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment.

doi:10.2169/internalmedicine.7098-21

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment.

Internal medicine (Tokyo, Japan) - 1 Nov 2021

Akutsu Noriyuki, Sasaki Shigeru, Matsui Takeshi, Akashi Hirofumi, Yonezawa Kazuhiko, Ishigami Keisuke, Tsujisaki Masayuki, Isshiki Hiroyuki, Yawata Atsushi, Yamaoka Satoshi, Ban Toshihiro, Adachi Takeya, Nakahara Seiya, Takagi Hideyasu, Nakachi Kohei, Tanaka Katsunori, Hirano Takehiro, Yamamoto Itaru, Kaneto Hiroyuki, Wagatsuma Kohei, Numata Yasunao, Nakase Hiroshi

Abstract excerpt

Objective The change in serum lipid levels by direct-acting antiviral (DAA) treatment for chronic hepatitis C varies depending on the type of DAA. How the lipid level changes induced by glecaprevir-pibrentasvir (G/P) treatment contribute to the clinical outcome remains unclear. We conducted a prospective observational study to evaluate the effectiveness of G/P treatment and the lipid level changes. Methods The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoisobutyric Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Cyclopropanes

Share to Lactams, Macrocyclic

Share to Leucine

Share to Pyrrolidines

Share to Quinoxalines

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 34024854
DOI: 10.2169/internalmedicine.7098-21
PMCID: PMC8627811

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment.PMID 34024854Read ↗

Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment.Semantic proximity Read ↗

Metabolic changes in chronic hepatitis C patients receiving direct acting antiviralsSemantic proximity Read ↗

Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3-year prospective cohort study.Semantic proximity Read ↗

The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients.Semantic proximity Read ↗

Genotype specific peripheral lipid profile changes with hepatitis C therapy.Semantic proximity Read ↗

Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs.Semantic proximity Read ↗

Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study.Semantic proximity Read ↗

INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION?Semantic proximity Read ↗

Brief Report: Differential Timing of Cholesterol Increase During Successful HCV Therapy: Impact of Type of Drug Combination.Semantic proximity Read ↗

Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol.Semantic proximity Read ↗

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.Semantic proximity Read ↗

Rapid normalization of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.